SHORT REPORT

Rapid degradation of an active formylglycine generating enzyme variant leads to a late infantile severe form of multiple sulfatase deficiency

Lars Schlotawa[1,6], Karthikeyan Radhakrishnan[2,3,6], Matthias Baumgartner[4], Regula Schmid[5], Bernhard Schmidt[3], Thomas Dierks*,[2] and Jutta Gärtner[1]

Multiple sulfatase deficiency (MSD) is a rare inborn error of metabolism affecting posttranslational activation of sulfatases by the formylglycine generating enzyme (FGE). Due to mutations in the encoding *SUMF1* gene, FGE's catalytic capacity is impaired resulting in reduced cellular sulfatase activities. Both, FGE protein stability and residual activity determine disease severity and have previously been correlated with the clinical MSD phenotype. Here, we report a patient with a late infantile severe course of disease. The patient is compound heterozygous for two so far undescribed *SUMF1* mutations, c.156delC (p.C52fsX57) and c.390A>T (p.E130D). In patient fibroblasts, mRNA of the frameshift allele is undetectable. In contrast, the allele encoding FGE-E130D is expressed. FGE-E130D correctly localizes to the endoplasmic reticulum and has a very high residual molecular activity *in vitro* (55% of wildtype FGE); however, it is rapidly degraded. Thus, despite substantial residual enzyme activity, protein instability determines disease severity, which highlights that potential MSD treatment approaches should target protein folding and stabilization mechanisms.

INTRODUCTION

Multiple Sulfatase Deficiency (MSD, MIM: #272200) affects the post-translational activation of newly synthesized sulfatases by the for-mylglycine-generating enzyme (FGE).[1] FGE is a glycoprotein of the endoplasmatic reticulum, 341 amino acids in length as mature enzyme, but is also secreted after N-terminal proteolytic processing.[2] The crystal structure shows a monomeric fold with two buried calcium ions, cysteine pairs stabilizing the core domain and two catalytic cysteines directly involved in formylglycine-generating redox activity[3–5] (Supplementary Figure S1). Mutations in the FGE-encoding *SUMF1* gene lead to instable protein and/or impaired FGE catalytic function resulting in reduced sulfatase activities. More than 30 different *SUMF1* mutations are known, most of them missense mutations that affect stability and residual molecular activity of mutant FGE, which both determine MSD disease severity.[6,7] The clinical phenotype includes the neonatal very severe, late infantile (severe and mild) and rare juvenile (mild) form. MSD combines main clinical symptoms of different single sulfatase deficiencies like dysmorphic features, neurodegenerative course of disease and ichthyotic skin rash. For patients with a functionally characterized mutation, a prediction of the clinical outcome is possible.[6–9] Here, we report a patient with two novel *SUMF1* mutations, one nonsense and one missense, describe the clinical consequences and correlate this with the molecular defects attributable to the missense mutation.

MATERIALS AND METHODS

SUMF1 mutations and enzyme activity assays
Mutational analysis of the *SUMF1* gene from genomic DNA of patient fibroblasts or leukocytes, as well as sulfatase and FGE activity assays were performed as described earlier.[10,11]

Expression studies
Cell culturing of patient skin fibroblasts and HT-1080 fibrosarcoma cells as well as stable transfection with pSB-FGE-His plasmids were described earlier.[6,7] The FGE-E130D mutation was created by site-directed mutagenesis according to the QuikChange Protocol (Stratagene, La Jolla, CA, USA) with Pfu polymerase and complementary primer pairs (coding sequence only: FGE_E130D-His_c 5′-CATGGATGCCTATGATGTCAGTAATACTG-3′).

Western blot and immunofluorescence studies
Aliquots of 50-µg cell protein, from cells of a confluent T75 cell culture flask grown in 10 ml medium for 24 h, and 40 µl aliquots of this medium were analyzed by SDS–polyacrylamide gel electrophoresis and western blot using a polyclonal FGE antibody or monoclonal His antibody (Sigma Aldrich, Munich, Germany) as described.[2] Endogenous FGE in skin fibroblasts or

[1]Department of Pediatrics and Pediatric Neurology, Georg August University Göttingen, Göttingen, Germany; [2]Bielefeld University, Department of Chemistry, Biochemistry I, Universitätsstr. Bielefeld, Germany; [3]Georg August University Göttingen, Department of Biochemistry II, Humboldtallee 23, Göttingen, Germany; [4]University Children's Hospital Zürich, Division of Metabolism, Steinwiessstr, Zürich, Switzerland; [5]Children's Hospital Winterthur, Brauerstr, Winterthur, Switzerland
[6]These authors contributed equally to this work.
*Correspondence: Dr T Dierks, Bielefeld University, Department of Chemistry, Biochemistry I, Universitätsstr. 25, Bielefeld 33615, Germany. Tel: +49 521 1062092; Fax: +49 521 1066014; E-mail: thomas.dierks@uni-bielefeld.de
Received 23 July 2012; revised 1 November 2012; accepted 5 December 2012; published online 16 January 2013

variant FGE in stably transfected HT-1080 cells was detected by indirect immunofluorescence using a polyclonal rabbit FGE antibody as described.[2] Monoclonal antibodies as organelle markers were used against PDI (Biomol, Hamburg, Germany), LAMP1 (Abcam, Cambridge, UK) and Golgi protein 58K (Abcam, Cambridge, UK). Confocal images were taken on a Leica TCS SP2 AOBS laser-scanning microscope and analyzed with the manufacturer's software (Leica, Solms, Germany).

FGE purification

HT-1080 cells stably overexpressing His-tagged wildtype or FGE-E130D were harvested, resuspended in buffer I (20 mM Tris-HCl, 40 mM imidazole, 500 mM sodium chloride, pH 8.0), and sonicated in presence of a protease inhibitor cocktail (Sigma Aldrich, Munich, Germany). The cell lysate was cleared by centrifugation at $100\,000 \times g$ for 20 min and loaded on a HisTrap column (GE Healthcare, Munich, Germany) using buffer I. The column was eluted in fractions of 1 ml with buffer II (20 mM Tris-HCl, 500 mM sodium chloride 500 mM imidazole, pH 8.0) running a gradient from 0–100% of buffer II in 25 min on a ÄKTA system (GE Healthcare). Appropriate elution fractions were pooled (6–8 ml), and concentrated to 50 μl using Amicon centrifugation filter units (Millipore, Billerica, MA, USA). The concentrated eluate was dialyzed against buffer III (20 mM Tris-HCl, pH 8), its FGE amount was determined and used for FGE activity assays.

Metabolic labeling and immunoprecipitation

HT-1080 cells stably expressing FGE-His or FGE-E130D-His were subjected to metabolic labeling with ^{35}S-methionine/cysteine and immunoprecipitation followed by phosphorimaging and densitometric quantification (PMI System, Biorad, Munich, Germany) as described.[7]

RESULTS

A patient with MSD displays a late infantile severe phenotype and reduced sulfatase activities

The female patient was born as the second child of non-consanguineous parents from Switzerland. In the first months she presented with muscular hypotonia and had a consecutive developmental delay. She was able to sit at age 14 months; at age 20 months she could grasp, babble, and was visually interactive. At age 22 months progressive leg spasticity became obvious, followed by paroxysmal tonic upward eye movements at age 25 months. At this time she started to lose motor and visual skills. Cerebral magnetic resonance imaging at age 27 months displayed a leukoencephalopathy pattern as seen in metachromatic leukodystrophy. Laboratory examinations revealed high-urine concentrations of glycosaminoglycans as well as clearly reduced activity of three cellular sulfatases tested (Table 1). At age 31 months she showed signs of tetraplegia, long eye lashes, a dry and scaly skin and no more reactions to noises. At 4 years

Table 1 Residual activities of selected sulfatases in patient fibroblasts

Patient No.	Disease type	ASA activity[a] nmol/h per mg (+/− SD) % of control	ASC activity[a] pmol/h per mg (+/− SD) % of control	Gal-6-S activity[a] nmol/h per mg (+/− SD) % of control
Contr.[b]		66 (+/−2.3) 100%	137 (+/−20) 100%	7.1 (+/−0.9) 100%
1[c]	LIS	14 (+/−1) **21%**	14 (+/−2) **10%**	1 (+/−0.1) **14%**

[a]Activities +/− SD were assayed in total cell lysates and calculated from three independent experiments.
[b]An unaffected fibroblast cell line served as control.
[c]% activity in patient compared to control is highlighted in bold.

Table 2 Clinical characterization of a new patient with MSD

Patient No.	Disease type[a]	Clinical symptoms[b]										Mutation	
		Mental retardation	Neurode-generation	Ichthyosis	Dysmorphism	Organomegaly	Sceletal changes	Postnatal symptoms	Heart involvement	Corneal clouding	Hydrocephalus	cDNA	Protein
	NVS[c]	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	c.979C>T / c.IVS3+5-8del	p.R327X / p.A149_A173del
	LIS[c]	+++	+++	++	+++	+++	++	+++	−	++	−	c.463C>T / c.463C>T	p.S155P / p.S155P
	LIM[c]	+++	++	+++	−	−	−	−	−	−	−	c.788G>T / c.788G>T	p.G263V / p.G263V
1[d]	LIS	+++	+++	++	+	−	+	+++	−	−	−	**c.390A>T** / c.156delC	**p.E130D** / p.C52fsX57

[a]Patients can be grouped into neonatal very severe (NVS), late infantile severe (LIS) and late infantile mild (LIM) forms of MSD according to manifestation and time point of appearance of each single symptom.
[b]+++, age of onset between 0–2 years of life; ++, 2–4 years; +, after 4 years; −, symptom is missing.
[c]Examples for disease groups in MSD[7]
[d]The clinical characteristics of the patient are highlighted in bold.

Figure 1 Localization, expression, activity and stability of FGE-E130D in HT-1080 cells. (**a**) Immunofluorescence detection of FGE (red) in stably transfected cells indicates that FGE-E130D, like wildtype FGE, co-localizes with the endoplasmatic reticulum marker protein disulfide isomerase (PDI, green), as shown in the merge. Untransfected cells (control) show endogenous FGE expression. (**b**) Western blot analysis of recombinant FGE-E130D, in comparison to wildtype FGE. Equal amounts of total cell lysate and medium were analyzed. Due to instability (see panel D) FGE-E130D is expressed at markedly reduced steady-state levels. The asterisk labels a specific band observed for FGE-E130D that is sensitive to glycosidase treatment (see text). (**c**) Residual activity of FGE-E130D was measured after partial purification of the protein from transfected cells. Defined amounts of FGE protein (27 ng, upper panel) were used for the assay. Measured activity is given relative to that of wildtype FGE, which was purified and incubated under identical conditions in parallel (mean values $+/-$ SD, $n = 3$). (**d**) Stability of FGE-E130D. After metabolic labeling, FGE protein was immunoprecipitated from cells and medium either immediately, 1.5 or 3 h after labeling. The intensity of bands was quantified and expressed as percentage of the protein amount present at 0 h (see lower panel). Note that about equal amounts of wildtype and mutant FGE were present at 0 h; however, FGE-E130D vanished almost completely from the cells within three hours and was not secreted.

and 1 month, coarse facies and dysostosis multiplex were detected, organomegaly was still absent. From the age of 39 months on she had irregular breathing attacks due to intermittent central hypoventilation. She died at the age of 5 years and 5 months (for a clinical synopsis see Table 2). The course of the disease in this patient could be classified as late infantile severe form of MSD. The early onset of neurodegeneration in the second year of life and the disease progression due to the manifestation of several additional clinical symptoms throughout her life is comparable to other described late infantile severe cases of MSD.[6–8]

Two new MSD causing SUMF1 mutations
In this patient we identified two so far unknown SUMF1 mutations. c.156delC leads to a frameshift and premature stop codon (p.C52fsX57). On the other allele, the single nucleotide exchange c.390A>T substitutes glutamate at position 130 of FGE by aspartate. At the mRNA level only the nucleotide exchange c.390A>T was detectable (data not shown).

FGE-E130D: correct intracellular localization, exceptionally high residual activity but drastically impaired intracellular stability and no secretion
Endogenous FGE-E130D in patient fibroblasts was hardly detectable (Supplementary Figure S2). For detailed analysis we expressed recombinant His-tagged FGE-E130D in human HT-1080 fibrosarcoma cells. FGE-E130D was correctly localized in the endoplasmic reticulum (Figure 1a). Western blot analysis (Figure 1b) revealed that FGE-E130D was not secreted, whereas a major fraction of wildtype FGE was secreted in a N-terminally truncated form

(38 kDa, starting at glutamate-73) due to proteolytic processing during secretion, as described previously.[2] Pulse-chase analysis by metabolic ^{35}S-labeling indicated a severe reduction of the intracellular stability of FGE-E130D, such that about 90% of the protein was degraded within 3 h (Figure 1d). Partially purified FGE-E130D displayed a residual FGE activity of 55 $+/-16\%$ (Figure 1c). Of note, the intracellular FGE-E130D was present in two molecular forms, one with a molecular mass of 41 kDa, comparable to wildtype FGE, and the other with 43–44 kDa. Endoglycosidase H treatment converted both forms to a 39-kDa form (data not shown).

DISCUSSION
MSD is still an untreatable disease. Thus, potential treatment approaches, and also genetic counseling, directly depend on thorough analyses of the functional consequences of human SUMF1 mutations on the clinical and biochemical phenotype. In a severely affected MSD patient with the late infantile onset of disease we identified and characterized two yet undescribed SUMF1 mutations, namely c.156delC and c.390A>T. As no corresponding mRNA for the single nucleotide deletion (p.C52fsX57) could be detected, probably in consequence of nonsense mediated decay,[12] the resulting sulfatase acitivities and apparently also the clinical phenotype are due to the missense mutation c.390A>T leading to expression of FGE-E130D protein.

The E130D mutation severely destabilizes FGE
Missense mutations represent the majority of genetic defects in MSD. For eight different missense mutations the instability of mutant FGE, as predicted from the crystal structure, could be verified by stability

and residual activity measurements.[4,6,7] In FGE-E130D the aspartate-130 side-chain is too short to position one of two calcium ions in the coordination plane. Consequently, interactions with adjacent residues are disturbed (Supplementary Figure S1) leading to protein destabilization and most likely early degradation.[13] Indeed, we could show that FGE-E130D is unable to pass endoplasmatic reticulum quality control, hence getting rapidly and completely degraded inside cells without entering into secretion. Interestingly, we found expression of FGE-E130D with two different molecular weights in all experiments and even after purification (Figures 1b-d). Both forms were sensitive to treatment with endoglycosidase H leading to a deglycosylated 39-kDa protein (data not shown). Details of these two alternative glycosylation patterns remain to be elucidated.

FGE-E130D displays very high residual catalytic activity

Up to now, all structurally impaired FGE variants showed clearly reduced specific enzyme activity.[6,7] The residual catalytic activities have been determined with purified FGE variants and reflect the true molecular enzymatic capacity of the mutant proteins *in vitro*. FGE-E130D shows a remarkable residual activity (55% compared with wildtype). So far, this is the highest residual activity that has been reported for a mutant FGE found in MSD. Such a high activity, if true *in vivo*, would be more than enough to maintain full sulfatase activation. However, the patient's compromised activities of sulfatases are in the range of no more than 10–20% of control activities, hence indicating massive FGE deficiency. This obviously is a consequence of the rapid degradation of FGE-E130D. Thus, protein instability is the leading molecular factor for pathophysiology in the reported patient.

Genotype-phenotype relationship in severe late infantile MSD

The clinical course of MSD in the reported patient corresponds to the late infantile severe form. Generally, MSD patients with high residual FGE activity, but instable protein reveal an attenuated course of disease.[6,7] In contrast to FGE-E130D, as reported here, all other mutant FGE proteins with high residual activity in former studies were found to be secreted. This indicates that these mutants at least in part were successful to pass intracellular control mechanisms of protein folding. The specific biochemical feature of a rapidly degraded (and hence non-secreted) FGE-E130D almost certainly contributes to the late infantile severe phenotype of our patient, thereby highlighting the importance of affected FGE stability and protein degradation as a main pathophysiological cause for MSD and as a reliable indicator of disease severity in case of high residual FGE activity. This does not exclude that other so far undiscovered disease modifiers also influence the clinical phenotypes of MSD patients. Our patient report underlines that potential future therapies should aim at protein stabilization mechanisms −in particular when residual mutant FGE activities are high.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

1 Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B: Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins. *Biochim Biophys Acta* 2009; **1793**: 710–725.
2 Preusser-Kunze A, Mariappan M, Schmidt B *et al*: Molecular characterization of the human Calpha-formylglycine-generating enzyme. *J Biol Chem* 2005; **280**: 14900–14910.
3 Roeser D, Preusser-Kunze A, Schmidt B *et al*: A general binding mechanism for all human sulfatases by the formylglycine-generating enzyme. *Proc Natl Acad Sci USA* 2006; **103**: 81–86.
4 Dierks T, Dickmanns A, Preusser-Kunze A *et al*: Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. *Cell* 2005; **121**: 541–552.
5 Mariappan M, Gande SL, Radhakrishnan K, Schmidt B, Dierks T, von Figura K: The non-catalytic N-terminal extension of formylglycine-generating enzyme is required for its biological activity and retention in the endoplasmic reticulum. *J Biol Chem* 2008; **283**: 11556–11564.
6 Schlotawa L, Steinfeld R, von Figura K, Dierks T, Gartner J: Molecular analysis of SUMF1 mutations: stability and residual activity of mutant formylglycine-generating enzyme determine disease severity in multiple sulfatase deficiency. *Human Mutat* 2008; **29**: 205.
7 Schlotawa L, Ennemann EC, Radhakrishnan K *et al*: SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency. *Eur J Hum Genet* 2011; **19**: 253–261.
8 Eto Y, Gomibuchi I, Umezawa F, Tsuda T: Pathochemistry, pathogenesis and enzyme replacement in multiple-sulfatase deficiency. *Enzyme* 1987; **38**: 273–279.
9 Blanco-Aguirre ME, Kofman-Alfaro SH, Rivera-Vega MR *et al*: Unusual clinical presentation in two cases of multiple sulfatase deficiency. *Pediatr Dermatol* 2001; **18**: 388–392.
10 Dierks T, Schmidt B, Borissenko LV *et al*: Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. *Cell* 2003; **113**: 435–444.
11 Rommerskirch W, von Figura K: Multiple sulfatase deficiency: catalytically inactive sulfatases are expressed from retrovirally introduced sulfatase cDNAs. *Proc Natl Acad Sci USA* 1992; **89**: 2561–2565.
12 Amrani N, Sachs MS, Jacobson A: Early nonsense: mRNA decay solves a translational problem. *Nat Rev Mol Cell Biol* 2006; **7**: 415–425.
13 Maattanen P, Gehring K, Bergeron JJ, Thomas DY: Protein quality control in the ER: the recognition of misfolded proteins. *Semin Cell Dev Biol* 2010; **21**: 500–511.

Supplementary Information accompanies the paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)